Patents by Inventor Gary A. Piazza

Gary A. Piazza has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of selectively inhibiting Ras-mediated tumor growth in humans
    Patent number: 9931315
    Abstract: Disclosed are compounds, for example, a compound of formula I, wherein R, R0, R1-R8, n, X, Y, Y?, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition for example, cancer, mediated by the ras gene.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: April 3, 2018
    Assignee: ADT Pharmaceuticals, Inc.
    Inventors: Gary A. Piazza, Xi Chen, Adam B. Keeton, Michael R. Boyd
  • METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES
    Publication number: 20180044314
    Abstract: Disclosed are compounds, for example, a compound of formula I, wherein R, R0, R1-R8, n, X, Y, Y?, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition for example, cancer, mediated by the ras gene.
    Type: Application
    Filed: December 16, 2015
    Publication date: February 15, 2018
    Inventors: Gary A. PIAZZA, Xi CHEN, Adam B. KEETON, Michael R. BOYD
  • Indenyl compounds, pharmaceutical compositions, and medical uses thereof
    Patent number: 9862698
    Abstract: Disclosed are compounds, for example, compounds of formula I, wherein R, R0, R1-R8, n, X, Y, Y?, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: January 9, 2018
    Assignee: ADT Pharmaceuticals, Inc.
    Inventors: Gary A. Piazza, Xi Chen, Adam B. Keeton, Michael R. Boyd
  • RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES
    Publication number: 20170342021
    Abstract: Disclosed are compounds, for example, compounds of formula (I), wherein R, R0 R1-R8, n, X, Y, Y1, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.
    Type: Application
    Filed: December 16, 2014
    Publication date: November 30, 2017
    Inventors: Gary A. Piazza, Xi Chen, Adam B. Keeton
  • Derivatives of celeboxib, use thereof and preparation thereof
    Patent number: 9388139
    Abstract: Derivatives of celecoxib that lack cyclooxygenase inhibitory activity but have improved PDE5 inhibitory activity are provided along with pharmaceutical compositions containing them for the treatment or prevention of cancer. Such compounds are expected to have reduced toxicity compared with celecoxib and other cyclooxygenase inhibitors, and greater efficacy compared with conventional PDE5 inhibitors. Derivatives of celecoxib are also suitable for treating chronic inflammatory conditions, erectile dysfunction, pulmonary hypertension, congestive heart failure, and enhancement of cognitive function.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: July 12, 2016
    Assignees: German University, Southern Research Institute
    Inventors: Gary A. Piazza, Ashraf H. Abadi
  • METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES
    Publication number: 20160175275
    Abstract: Disclosed are compounds, for example, a compound of formula I, wherein R, R0, R1-R8, n, X, Y, Y?, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition for example, cancer, mediated by the ras gene.
    Type: Application
    Filed: February 29, 2016
    Publication date: June 23, 2016
    Applicant: ADT PHARMACEUTICALS, INC.
    Inventors: Gary A. Piazza, Xi Chen, Adam B. Keeton, Michael R. Boyd
  • INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF
    Publication number: 20160168113
    Abstract: Disclosed are compounds, for example, compounds of formula I, wherein R, R0, R1-R8, n, X, Y, Y?, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.
    Type: Application
    Filed: December 16, 2014
    Publication date: June 16, 2016
    Inventors: Gary A. Piazza, Xi Chen, Adam B. Keeton, Michael R. Boyd
  • METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES
    Publication number: 20160168108
    Abstract: Disclosed are compounds, for example, a compound of formula I, wherein R, R0, R1-R8, n, X, Y, Y?, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition for example, cancer, mediated by the ras gene.
    Type: Application
    Filed: December 16, 2014
    Publication date: June 16, 2016
    Inventors: Gary A. Piazza, Xi Chen, Adam B. Keeton, Michael R. Boyd
  • Derivatives of sulindac, use thereof and preparation thereof
    Patent number: 9365528
    Abstract: Derivatives of sulindac that lack cyclooxygenase inhibitory activity are provided along with pharmaceutical compositions containing them and use for treatment or prevention of cancer. The derivatives of sulindac are also suitable for treating chronic inflammatory conditions. A method for preparing the derivatives is also provided.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: June 14, 2016
    Assignee: Southern Research Institute
    Inventors: Robert Reynolds, Bini Mathew, Gary A. Piazza
  • TREATMENT AND DIAGNOSIS OF CANCER AND PRECANCEROUS CONDITIONS USING PDE10A INHIBITORS AND METHODS TO MEASURE PDE10A EXPRESSION
    Publication number: 20160143912
    Abstract: Disclosed are methods for treating cancer and precancerous conditions with PDE10A specific inhibitors and diagnosis of neoplastic diseases based on elevated levels of PDE10A.
    Type: Application
    Filed: July 11, 2014
    Publication date: May 26, 2016
    Applicant: University of South Alabama
    Inventor: Gary A. Piazza
  • Tetrahydro-beta-carboline derivatives, synthesis and use thereof
    Patent number: 9169247
    Abstract: Certain 2-halophenyl, 2,4-dihalophenyl (e.g. 2,4-dichlorophenyl), 3,4-dichlorophenyl (e.g. 3,4-dichlorophenyl), 2,6-dichlorophenyl (2,6-dichlorophenyl) and 2,5-diakoxyphenyl (e.g. 2,5-dimethoxyphenyl) derivatives of tetrahydro-?-carbolines are provided, along with their pharmaceutically acceptable salts; prodrugs and solvates, and compositions containing the compounds. The compounds are useful for the prevention and treatment of cancer, and other indications where PDE5 inhibitors have shown benefits including erectile dysfunction, pulmonary hypertension, enhancing cognitive function, cystic fibrosis, or enhancing the activity of conventional chemotherapeutic drugs. Methods for fabricating the compounds are also provided.
    Type: Grant
    Filed: November 19, 2010
    Date of Patent: October 27, 2015
    Assignee: Southern Research Institute
    Inventors: Gary A. Piazza, Ashraf H. Abadi
  • DERIVATIVES OF CELEBOXIB, USE THEREOF AND PREPARATION THEREOF
    Publication number: 20140171477
    Abstract: Derivatives of celecoxib that lack cyclooxygenase inhibitory activity but have improved PDE5 inhibitory activity are provided along with pharmaceutical compositions containing them for the treatment or prevention of cancer. Such compounds are expected to have reduced toxicity compared with celecoxib and other cyclooxygenase inhibitors, and greater efficacy compared with conventional PDE5 inhibitors. Derivatives of celecoxib are also suitable for treating chronic inflammatory conditions, erectile dysfunction, pulmonary hypertension, congestive heart failure, and enhancement of cognitive function.
    Type: Application
    Filed: March 16, 2012
    Publication date: June 19, 2014
    Inventors: Gary A. Piazza, Ashraf H. Abadi
  • DERIVATIVES OF SULINDAC, USE THEREOF AND PREPARATION THEREOF
    Publication number: 20140094492
    Abstract: Derivatives of sulindac that lack cyclooxygenase inhibitory activity are provided along with pharmaceutical compositions containing them and use for treatment or prevention of cancer. The derivatives of sulindac are also suitable for treating chronic inflammatory conditions. A method for preparing the derivatives is also provided.
    Type: Application
    Filed: March 30, 2012
    Publication date: April 3, 2014
    Applicant: Southern Research Institute
    Inventors: Robert Reynolds, Bini Mathew, Gary A. Piazza
  • TETRAHYDRO-beta-CARBOLINE DERIVATIVES, SYNTHESIS AND USE THEREOF
    Publication number: 20120309781
    Abstract: Certain 2-halophenyl, 2,4-dihalophenyl (e.g. 2,4-dichlorophenyl), 3,4-dichlorophenyl (e.g. 3,4-dichlorophenyl), 2,6-dichlorophenyl (2,6-dichlorophenyl) and 2,5-diakoxyphenyl (e.g. 2,5-dimethoxyphenyl) derivatives of tetrahydro-?-carbolines are provided, along with their pharmaceutically acceptable salts; prodrugs and solvates, and compositions containing the compounds. The compounds are useful for the prevention and treatment of cancer, and other indications where PDE5 inhibitors have shown benefits including erectile dysfunction, pulmonary hypertension, enhancing cognitive function, cystic fibrosis, or enhancing the activity of conventional chemotherapeutic drugs. Methods for fabricating the compounds are also provided.
    Type: Application
    Filed: November 19, 2010
    Publication date: December 6, 2012
    Applicant: Southern Research Institute
    Inventors: Gary A. Piazza, Ashraf H. Abadi
  • Derivatives of sulindac, use thereof and preparation thereof
    Patent number: 8044048
    Abstract: Derivatives of sulindac are provided along with pharmaceutical compositions containing them and use for precancerous conditions and treating cancer. Derivatives of sulindac are also suitable for treating chronic inflammatory conditions. A method for preparing the derivatives is also provided.
    Type: Grant
    Filed: January 4, 2007
    Date of Patent: October 25, 2011
    Assignee: Southern Research Institute
    Inventors: Gary Piazza, Robert Reynolds
  • 5-QUINOLINONE AND IMIDAZOPYRIDINE COMPOUNDS AND USE THEREOF
    Publication number: 20110178106
    Abstract: 5-Quinolinone and Imidazopyrimidine compounds are provided that are useful for inhibiting the efflux of any therapeutic agent that is a MRP1 substrate. Also provided is a method for screening to identify additional MRP1 inhibitors.
    Type: Application
    Filed: July 10, 2009
    Publication date: July 21, 2011
    Applicant: SOUTHERN RESEARCH INSTITUTE OFFICE OF COMMERCIALIZ
    Inventors: Joseph A. Maddry, Adam Keeton, Jason Whitt, Gary Piazza
  • Derivatives of sulindac, use thereof and preparation thereof
    Publication number: 20070244122
    Abstract: Derivatives of sulindac are provided along with pharmaceutical compositions containing them and use for precancerous conditions and treating cancer. Derivatives of sulindac are also suitable for treating chronic inflammatory conditions. A method for preparing the derivatives is also provided.
    Type: Application
    Filed: January 4, 2007
    Publication date: October 18, 2007
    Applicant: Southern Research Institute Office of Commercialization and Intellectual Property
    Inventors: Gary Piazza, Robert Reynolds
  • Method of inhibiting neoplastic cells with indole derivatives
    Patent number: 7115647
    Abstract: A method for inhibiting neoplastic cells and related conditions by exposing them to substituted indole derivatives.
    Type: Grant
    Filed: February 7, 2002
    Date of Patent: October 3, 2006
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Rifat Pamukcu, Gary A. Piazza
  • Methods for identifying compounds for inhibition of neoplastic lesions, and pharmaceutical compositions containing such compounds
    Publication number: 20050244914
    Abstract: This invention provides pharmaceutical compositions containing compounds for the treatment of neoplasia in mammals. The phosphodiesterase inhibitory activity of a compound is determined along with COX inhibitory activity. Growth inhibitory and apoptosis inducing effects on cultured tumor cells are also determined. Compounds that exhibit phosphodiesterase inhibiton, growth inhibition and apoptosis induction, but prefereably not substantial prostaglandin inhibitory activity, are desirable for the treatment of neoplasia.
    Type: Application
    Filed: July 7, 2005
    Publication date: November 3, 2005
    Inventors: Li Liu, Bing Zhu, Han Li, W. Thompson, Rifat Pamukcu, Gary Piazza
  • Diagnostic methods for neoplasia
    Patent number: 6875575
    Abstract: This invention provides a method for diagnosing a patient with neoplasia.
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: April 5, 2005
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Rifat Pamukcu, Gary A. Piazza